标题
Tumor heterogeneity in the clinic: is it a real problem?
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 6, Issue 2, Pages 43-51
出版商
SAGE Publications
发表日期
2013-12-21
DOI
10.1177/1758834013517414
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
- (2017) S. Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Liquid biopsy: monitoring cancer-genetics in the blood
- (2013) Emily Crowley et al. Nature Reviews Clinical Oncology
- Circulating tumour cells and cell-free DNA as tools for managing breast cancer
- (2013) Leticia De Mattos-Arruda et al. Nature Reviews Clinical Oncology
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- The tumor microenvironment is a dominant force in multidrug resistance
- (2012) Ana Luísa Correia et al. DRUG RESISTANCE UPDATES
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
- (2012) J. R. Westin et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
- (2012) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Overcoming implementation challenges of personalized cancer therapy
- (2012) Funda Meric-Bernstam et al. Nature Reviews Clinical Oncology
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience
- (2011) H. El-Osta et al. ONCOLOGIST
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
- (2011) Filip Janku et al. PLoS One
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
- (2010) A Chakrabarty et al. ONCOGENE
- Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
- (2010) R. J. Leary et al. Science Translational Medicine
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started